275 related articles for article (PubMed ID: 33321344)
1. Retinal cotton wool spot associated with cladribine therapy for multiple sclerosis.
Gummi R; Walsh RD; Ahmad B
Mult Scler Relat Disord; 2021 Feb; 48():102661. PubMed ID: 33321344
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment.
Dersch R; Wehrum T; Fähndrich S; Engelhardt M; Rauer S; Berger B
Mult Scler; 2020 Sep; 26(10):1264-1266. PubMed ID: 32762488
[TBL] [Abstract][Full Text] [Related]
3. Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis.
Brochet B; Hupperts R; Langdon D; Solari A; Piehl F; Lechner-Scott J; Montalban X; Selmaj K; Valis M; Rejdak K; Havrdova EK; Patti F; Alexandri N; Nolting A; Keller B
Mult Scler Relat Disord; 2022 Jan; 57():103385. PubMed ID: 35158476
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study.
Zanetta C; Rocca MA; Meani A; Martinelli V; Ferrè L; Moiola L; Filippi M
J Neurol; 2023 Jul; 270(7):3553-3564. PubMed ID: 37027018
[TBL] [Abstract][Full Text] [Related]
5. Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study.
Brochet B; Solari A; Lechner-Scott J; Piehl F; Langdon D; Hupperts R; Selmaj K; Patti F; Brieva L; Maida EM; Alexandri N; Smyk A; Nolting A; Keller B; Montalban X; Kubala Havrdova E
Mult Scler; 2023 Dec; 29(14):1808-1818. PubMed ID: 37978852
[TBL] [Abstract][Full Text] [Related]
6. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis.
Cook S; Leist T; Comi G; Montalban X; Giovannoni G; Nolting A; Hicking C; Galazka A; Sylvester E
Mult Scler Relat Disord; 2019 Apr; 29():157-167. PubMed ID: 30885374
[TBL] [Abstract][Full Text] [Related]
7. Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment.
Schönfelder K; Schuh H; Pfister F; Krämer J; Eisenberger U; Skuljec J; Hackert J; Ruck T; Pfeuffer S; Fleischer M; Gäckler A; Hagenacker T; Kribben A; Meuth SG; Kleinschnitz C; Pul R
Mult Scler; 2021 Oct; 27(12):1960-1964. PubMed ID: 34165361
[TBL] [Abstract][Full Text] [Related]
8. Cladribine tablets for highly active relapsing-remitting multiple sclerosis in Poland: a real-world, multi-centre, retrospective, cohort study during the COVID-19 pandemic.
Stępień A; Pogoda-Wesołowska A; Tokarz-Kupczyk E; Słowik A; Puz P; Adamczyk-Sowa M; Kurkowska-Jastrzębska I; Kułakowska A; Chorąży M; Piasecka-Stryczyńska K; Jamróz-Wiśniewska A; Bartosik-Psujek H; Rejdak K
Neurol Neurochir Pol; 2023; 57(4):371-378. PubMed ID: 37490356
[TBL] [Abstract][Full Text] [Related]
9. Disseminated nocardiosis after cladribine treatment for relapsing remitting multiple sclerosis: a case report.
Deana C; Bagatto D; Battezzi A; Pecori D; Lorenzut S; Tuniz F
J Neurol; 2022 Aug; 269(8):4557-4559. PubMed ID: 35352170
[No Abstract] [Full Text] [Related]
10. Immunological consequences of cladribine treatment in multiple sclerosis: A real-world study.
Rolfes L; Pfeuffer S; Huntemann N; Schmidt M; Su C; Skuljec J; Aslan D; Hackert J; Kleinschnitz K; Hagenacker T; Pawlitzki M; Ruck T; Kleinschnitz C; Meuth SG; Pul R
Mult Scler Relat Disord; 2022 Aug; 64():103931. PubMed ID: 35690010
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
Giovannoni G; Soelberg Sorensen P; Cook S; Rammohan K; Rieckmann P; Comi G; Dangond F; Adeniji AK; Vermersch P
Mult Scler; 2018 Oct; 24(12):1594-1604. PubMed ID: 28870107
[TBL] [Abstract][Full Text] [Related]
12. High persistence and low adverse events burden in cladribine treated MS patients from Argentina.
Negrotto L; Iut VC; Etchepare A; D'Eramo M; Grinspan A; Assefi A
Mult Scler Relat Disord; 2022 Dec; 68():104403. PubMed ID: 36544327
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
Cook S; Vermersch P; Comi G; Giovannoni G; Rammohan K; Rieckmann P; Sørensen PS; Hamlett A; Miret M; Weiner J; Viglietta V; Musch B; Greenberg SJ;
Mult Scler; 2011 May; 17(5):578-93. PubMed ID: 21228029
[TBL] [Abstract][Full Text] [Related]
14. Effects of Postponing Treatment in the Second Year of Cladribine Administration: Clinical Trial Simulation Analysis of Absolute Lymphocyte Counts and Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis.
Terranova N; Hicking C; Dangond F; Munafo A
Clin Pharmacokinet; 2019 Mar; 58(3):325-333. PubMed ID: 29992396
[TBL] [Abstract][Full Text] [Related]
15. Cladribine for multiple sclerosis.
Drug Ther Bull; 2018 Feb; 56(2):21-24. PubMed ID: 29449328
[TBL] [Abstract][Full Text] [Related]
16. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Giovannoni G; Comi G; Cook S; Rammohan K; Rieckmann P; Soelberg Sørensen P; Vermersch P; Chang P; Hamlett A; Musch B; Greenberg SJ;
N Engl J Med; 2010 Feb; 362(5):416-26. PubMed ID: 20089960
[TBL] [Abstract][Full Text] [Related]
17. Remission of early persistent cladribine-induced neutropenia after filgrastim therapy in a patient with Relapsing - Remitting Multiple Sclerosis.
Maniscalco GT; Annunziata M; Ranieri A; Alfieri G; Renna R; Iorio WD; Guarcello G; Cerillo I; Improta G; Florio C
Mult Scler Relat Disord; 2020 Aug; 43():102151. PubMed ID: 32417665
[TBL] [Abstract][Full Text] [Related]
18. The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets.
Butzkueven H; Moore N; Aydemir A; Sõnajalg J; Bezemer I; Korhonen P; Sabidó M;
Curr Med Res Opin; 2022 Jul; 38(7):1167-1176. PubMed ID: 35357268
[TBL] [Abstract][Full Text] [Related]
19. Safety and effectiveness of cladribine tablets for multiple sclerosis: Results from a single-center real-world cohort.
Aerts S; Khan H; Severijns D; Popescu V; Peeters LM; Van Wijmeersch B
Mult Scler Relat Disord; 2023 Jul; 75():104735. PubMed ID: 37192586
[TBL] [Abstract][Full Text] [Related]
20. Cladribine (Mavenclad) for multiple sclerosis.
Med Lett Drugs Ther; 2019 Jul; 61(1577):118-120. PubMed ID: 31381552
[No Abstract] [Full Text] [Related]
[Next] [New Search]
